Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib to Prevent Gluten-induced Celiac Enteropathy and Symptoms in Celiac Disease Patients in Remission processed this data on February 26, 2024. Link to the current record.

Recruitment Status

RECRUITING (See Contacts and Locations)
Verified February 2024 by Massachusetts General Hospital, Pfizer


Massachusetts General Hospital

Information Provided by (Responsible Party)

Alessio Fasano Identifier

Other Study ID Numbers: 2022P002248
First Submitted: November 1, 2022
First Posted: December 5, 2022
Last Update Posted: February 28, 2024
Last Verified: February 2024
History of Changes

Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating., a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.

Information on is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.

Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.

For more information about using the information on, please also see Terms and Conditions.

See also the Web Policies and Notices for the NIH web site.

Study Description

The investigators are proposing a double blind, placebo-controlled trial to establish safety and efficacy of ritlecitinib to prevent gluten-induced celiac enteropathy and symptoms in celiac disease (CeD) patients in remission. The results of this study will impact the therapeutic options in the future for individuals with CeD.

Participants will take placebo capsule or ritlecitinib 200 mg capsule once per day. Both will be taken orally. All participants will take 10g gluten once per day, for a total of 21 days. Gluten will be taken orally by mixing the gluten powder into either hot chocolate or apple sauce. If participant unable to tolerate 10g of gluten daily, they will have the option to decrease to 5g daily after Day 3 of study.
Condition or Disease Intervention/Treatment
  • Celiac Disease
  • Drug: Ritlecitinib
  • Drug: Placebo
  • Other: Gluten

Study Design

Study TypeInterventional
Anticipated Enrollment30 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
Primary PurposeTreatment
Official TitleDouble Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib to Prevent Gluten-induced Celiac Enteropathy and Symptoms in Celiac Disease Patients in Remission
Study Start DateMarch 1, 2023
Anticipated Primary Completion DateAugust 1, 2025
Anticipated Study Completion DateAugust 1, 2025

Groups and Cohorts

Group/ CohortIntervention/ Treatment
  • Ritlecitinib
    • 10g gluten + 200mg of Ritlecitinib
  • Drug: Ritlecitinib
    • 200mg Ritlecitinib
  • Other: Gluten
    • Placebo
      • 10g gluten + placebo
    • Drug: Placebo
      • Other: Gluten

        Outcome Measures

        Primary Outcome Measures

        1. Change in Small Intestinal Histology based on Vh:Cd ratio [Through study completion, average of 1 year.]
          Characterize the gluten-challenge induced changes in small intestine histology using standard for Celiac Disease histological assessments related to villus height to crypt depth ratio [Vh:Cd]
        2. Patient Reported Outcome Surveys (CeD PRO survey evaluation) [Through study completion, average of 1 year.]
          Patient Reported Outcomes (PROs) - CeD PRO evaluation of gluten challenge-triggered symptoms

        Secondary Outcome Measures

        1. Serology [Through study completion, average of 1 year.]
          Serology tTG IgA, EMA, DGP
        2. Changes in Small Intestinal Histology of intraepithelial lymphocytes (IELs) [Through study completion, average of 1 year.]
          Characterize the gluten-challenge induced changes in small intestine histology using standard for Celiac Disease histological assessments related to intraepithelial lymphocyte counts

        Eligibility Criteria

        Ages Eligible for Study 18 Years to 75 Years (Adult, Older Adult)
        Sexes Eligible for Study All
        Accepts Healthy Volunteers No
        Inclusion Criteria
        • Male and/or female subjects (including Women of Childbearing Potential (WOCBP)) ≥18 years to ≤75 years of age at the time of informed consent
        • Have a body mass index ≥17 to <40 (and a body weight >45 kg at the Screening Visit).
        • Agree to make every effort to avoid pregnancy (see lifestyle outline below) from the time of signing the informed consent throughout the duration of the trial, if the subject is a woman of childbearing potential and sexually active with a non-sterilized male partner.
        • Have well controlled biopsy-proven CeD, compliant with a GFD for ≥6 months preceding Screening, with resolution of CeD symptoms, normalization of CeD serology (defined as
        • Be HLA-DQ2.5 and/or HLA-DQ8 positive, as assessed at screening. If subjects have already been genotyped, then results from previous testing may be used in lieu of genotyping at screening.
        • Must obtain negative SARS-CoV-2 test result (molecular diagnostic such as RT-PCR or RT-qPCR at the discretion of the investigator) at the screening visit and both timepoints prior to endoscopy (day 1 &15).
        • Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
        • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
        • Agree to avoid strenuous exercise during the study, especially within one week prior to the scheduled study visits and maintain adequate hydration (recommended)
        • Avoid consumption of grapefruit juice exceeding 8 ounces (~240 ml) total in a day while in the study (recommended)
        • Agree to the following contraception criteria:
        • Subjects who are, in the opinion of the investigator, sexually active and at risk for pregnancy with their partner(s) must agree to use 2 methods of effective contraception (at least 1 highly effective method) throughout the study and for at least 28 days after the last dose of investigational product. The investigator or his or her designee, in consultation with the subject, will confirm that the subject has selected 2 appropriate methods of contraception for the individual subject and his/her partner(s) from the list of permitted contraception methods (see below) and will confirm that the subject has been instructed in their consistent and correct use. At time points indicated in the Schedule of Activities, the investigator or designee will inform the subject of the need to use 2 methods of effective contraception (at least 1 highly effective method) consistently and correctly and document the conversation, and the subject's affirmation, in the subject's chart. In addition, the investigator or designee will instruct the subject to call immediately if 1 or both selected contraception methods are discontinued or if pregnancy is known or suspected in the subject or partner.
        • Highly effective methods of contraception are those that, alone or in combination, result in a failure rate of less than 1% per year when used consistently and correctly (i.e., perfect use) and include the following:
        • Implantable progestogen-only hormone contraception associated with inhibition of ovulation.
        • Intrauterine device (IUD).
        • Intrauterine hormone-releasing system (IUS).
        • Bilateral tubal occlusion or tubal ligation.
        • Vasectomized partner: Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. The spermatogenesis cycle is approximately 90 days
        • Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation: oral; intravaginal; transdermal
        • Progestogen-only hormone contraception associated with inhibition of ovulation: oral; injectable.
        • Sexual abstinence: Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
        • Male condom or female condom: All sexually active male subjects must agree to prevent potential transfer to and exposure of partner(s) to drug through ejaculate by using a condom consistently and correctly, beginning with the first dose of investigational product and continuing for at least 28 days after the last dose of investigational product. Male subjects must refrain from donating sperm during the study and for 90 days after the last dose of investigational product.
        Exclusion Criteria
        • Have a history of gluten triggered acute symptoms (≤24 hours after gluten exposure), and/or severe symptoms (abdominal pain interfering with daily activities, diarrhea with >5 stools/day), and/or prolonged symptoms (duration >7 days).
        • A history of any abdominal or pelvic surgery <3 months before trial enrollment; prior surgery abdominal or pelvic surgery (e.g., cholecystectomy, appendectomy, and hysterectomy) are permitted if performed >3 months before trial enrollment.
        • Subjects considered in imminent need for surgery or with elective surgery scheduled to occur during the study
        • Have a positive or borderline positive IgA anti-tissue transglutaminase serology at Screening (defined as >/= 2 times the upper limit of normal).
        • Have Marsh 3a-c determined by pathology at Screening Endoscopy
        • A diagnosis of any other inflammatory gastrointestinal disorder
        • Ongoing immunosuppression or receive any treatment within 3 months the starting of the trial that might alter T cell repertoire or phenotype.
        • Has a confirmed history of a SARS-CoV-2 infection within the previous 2 months of the screening visit.
        • Any history of either untreated or inadequately treated latent or active TB infection by Interferon Gamma Release Assay during screening or within 12 weeks prior to randomization, current treatment for active or latent TB infection or evidence of currently active TB by chest x-ray, residing with or frequent close contact with individual(s) with active TB.
        • Positive screening for HIV, Hepatitis B, Hepatitis C.

        Contacts and Locations

        Sponsors and Collaborators Massachusetts General Hospital, Pfizer
        • Massachusetts General Hospital | Boston, Massachusetts, United States, 02114
        • Principal Investigator: Alessio Fasano, MD, Massachusetts General Hospital

        More Information

        Additional Relevant MeSH Terms

        • Celiac Disease
        • Malabsorption Syndromes
        • Intestinal Diseases
        • Gastrointestinal Diseases
        • Digestive System Diseases
        • Metabolic Diseases